A pilot phase 2a, randomized, double-blind, placebo-controlled study to explore the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir at two dose levels in non-hospitalized adults with respiratory syncytial virus infection.

OBJECTIVES: To assess the antiviral effect, clinical outcomes, and safety of the respiratory syncytial virus (RSV) fusion inhibitor rilematovir in non-hospitalized RSV-infected adults. METHODS: This phase 2a, double-blind, multicentre study randomly assigned RSV-positive adult outpatients ≤5 days from symptom onset 1:1:1 to receive rilematovir 500 mg, 80 mg, or placebo once-daily for 7 days. Antiviral effect was assessed by RSV RNA viral load (VL), measured by quantitative RT-PCR, and Kaplan-Meier (KM) estimates of time to undetectable VL. Clinical course was assessed by KM estimates of median time to resolution of key RSV symptoms assessed through patient-reported outcomes. RESULTS: RSV-positive patients (n = 72) were randomly assigned; 66 had confirmed RSV infection and received rilematovir 500 mg (n = 23), 80 mg (n = 21) or placebo (n = 22). Differences versus placebo in mean RSV RNA VL area under the curve (90% CI) through days 3, 5 and 8, respectively, were 0.09 (-0.837; 1.011), -0.10 (-2.171; 1.963), and -1.03 (-4.746; 2.682) log10 copies.day/mL for rilematovir 500 mg, and 1.25 (0.291; 2.204), 2.53 (0.430; 4.634), and 3.85 (0.097; 7.599) log10 copies.day/mL for rilematovir 80 mg. KM estimates of median (90% CI) time-to-first confirmed undetectable VL were 5.9 (3.85; 6.90), 8.0 (6.86; 12.80) and 7.0 (6.62; 10.88) days and 5.7 (2.93; 7.01), 8.1 (6.74; 12.80) and 7.9 (6.62; 11.74) days in patients with symptom onset ≤3 days, for rilematovir 500 mg, 80 mg, and placebo, respectively. KM estimates of median (90% CI) time to resolution of key RSV symptoms were 7.1 (5.03; 11.43), 7.6 (5.93; 8.32), and 9.6 (5.95; 14.00) days for rilematovir 500 mg, 80 mg, and placebo, respectively; and in patients with symptom onset ≤3 days, median 8.0, 7.6, and 11.8 days, respectively. DISCUSSION: Rilematovir use, initiated early, suggests a potential clinical benefit in RSV-infected adults, with data supporting development of RSV therapeutic options. TRIAL REGISTRATION: This study is registered with clinicaltrials.gov (NCT03379675).

Fibromixoma de septum nasal: Presentación de un caso / Nasal septum fibromyxoma: A case report

Introducción: El fibromixoma es una lesión benigna poco frecuente cuya etiología aún es controversial. Rara vez aparece en cabeza y cuello, en cuyo caso afecta con mayor frecuencia a la mandíbula. Objetivo: Presentar un caso poco frecuente de fibromixoma derivado de septum nasal. Material y métodos: A continuación se describe el caso de un paciente masculino de 50 años con diagnóstico de fibromixoma proveniente del septum nasal, que se presento con epífora como única manifestación clínica; se trató quirúrgicamente con resección total endoscópica. Discusión: Son pocos los casos de fibromixoma documentados que comprometen la región nasosinusal. Conclusiones: Es importante considerar al fibromixoma dentro de los tumores del septum nasal, que a pesar de su naturaleza benigna, son lesiones que requieren resecciones amplias por su comportamiento localmente agresivo.

Introduction: Fibromyxoma is an uncommon benign lesion whose etiology is still controversial. Rarely, it appears in head and neck where the jaw is the region most often affected. Objective: To present a rare case of nasal septum fibromyxoma. Methods: We present the case of a 50 year old male with the diagnosis of fibromyxoma from the nasal septum, who presented with epiphora as the only clinical manifestation. It was treated surgically with complete endoscopic resection. Discussion: There are few cases of fibromyxoma documented that compromise sinonasal region. Conclusions: It is important to consider fibromyxoma within the differential diagnosis of nasal septum tumors, which despite its benign nature, requires extensive resections due to its locally aggressive behavior.